Implantica AG Stock

IMP A SDB

SE0014855029

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm 13:00:00 2026-10-27 EDT			5-day change	1st Jan Change
64.40 ^SEK	+2.38%		+4.55%	+28.54%

10-27	Implantica prepares for first RefluxStop surgeries in the US	FW
09-29	Implantica AG Launches RefluxStop® in U.S. Market at 2026 American Foregut Society Meeting	CI

Last Transcript: Implantica AG

Implantica AG - Analyst/Investor Day

09-11

More transcripts

Analysts' recommendations: Implantica AG

08-24	Pareto reiterates buy on Implantica, raises target price to 90 kronor	FW
08-24	Pareto Securities raises its target price for Implantica to 90 kronor (73), reiterates buy	FW
25-10-16	Pareto Raises Target Price for Implantica as FDA Approval Nears Turning Point	FW
25-10-16	Pareto Securities Raises Target Price for Implantica to 73 Kronor (54), Reiterates Buy	FW
25-10-13	Implantica Completes Key Milestone in US FDA Review for Acid Reflux Device	MT

More recommendations

News in other languages: Implantica AG

08-24	Quadient séduit, Stellantis souffre
08-21	Bourse : Ipsen boucle le rachat de Kartos, la banque italienne en ébullition, Holcim s'offre Fermacell
25-07-01	Les actions en mouvement : Walmart met à mal VusionGroup
25-06-04	Les actions en mouvement : contrats majeurs et commandes importantes
24-09-18	Actualización de las fuertes variaciones del día: Implantica revoluciona el tratamiento del reflujo, Novo Nordisk se enfrenta a la incertidumbre

More news

Managers and Directors: Implantica AG

Manager	Title	Age	Since
Peter Forsell CEO	Chief Executive Officer	72	2014-12-31
Andreas Öhrnberg DFI	Director of Finance/CFO	48	2019-12-31
Stephan Siegenthaler PRN	Corporate Officer/Principal	69	-

Director	Title	Age	Since
Liselott Kilaas CHM	Chairman	67	2019-12-31
Johan Bojs BRD	Director/Board Member	62	2019-12-31
Tomas Puusepp BRD	Director/Board Member	71	2019-12-31

More insiders

Implantica AG is Lichtenstein-based medical technology Company, whose mission is to provide effective treatment for serious health conditions and to improve patients' life through the use of advanced technologies in the human body, ultimately aiming to reduce costs and increase efficiency in the healthcare System. The therapies developed by Implantica are based on implants that are inserted into the patient's body and remain in the body permanently or semi-permanently to replace bodily functions and/or treat diseases. The Company focuses on the discovery, development and prospective commercialization of medical products and implants that are intended for use in different treatment fields like in the area of gastrointestinal surgery and urology. The Company's lead product is RefluxStop, a passive, implant to prevent gastroesophageal reflux disease (GERD).

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

11-18 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-10-27	SEK 64.40	+2.38%	35,221
26-10-26	SEK 62.90	+1.45%	15,665
26-10-23	SEK 62.00	-0.48%	33,498
26-10-22	SEK 62.30	0.00%	33,608
26-10-21	SEK 62.30	+1.14%	10,746

Delayed Quote Nasdaq Stockholm

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.817EUR

Average target price

8.141EUR

Spread / Average Target

+39.94%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Implantica AG

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Implantica AG

Company calendar

Market Cap	405M 451M 374M 339M 634M 42.87B 642M 4.48B 1.78B 22.47B 1.69B 1.66B 71.26B	P/E 2026 *	-19.5x	P/E 2027 *	-15.8x
Enterprise Value	377M 420M 348M 316M 590M 39.9B 597M 4.17B 1.66B 20.92B 1.58B 1.54B 66.33B	EV / Sales 2026 *	110x	EV / Sales 2027 *	44.1x
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	IMP A SDB	Delayed
Tradegate	8IM1	Real-time
Deutsche Boerse AG	8IM1	Delayed
Börse Stuttgart	8IM1	Delayed
Boerse Muenchen	8IM1	Real-time

09-29	Implantica's RefluxStop® U.S. market launch kicked off at the 2026 American Foregut Society Meeting, receiving an outstanding reception	AQ
09-14	Implantica's Capital Markets Day webcast available on demand	AQ
09-11	Implantica's Capital Markets Day webcast available on demand	AQ
09-08	Implantica to host Capital Markets Day in Stockholm on September 9	AQ
08-25	Implantica to host Capital Markets Day in Stockholm on September 9	AQ

1 day	+2.38%
1 week	+4.55%
Current month	-13.44%
1 month	+9.15%
3 months	+9.34%
6 months	+37.31%
Current year	+28.54%

1 week	61	64.6
1 month	60.5	78
Current year	38	80.3
1 year	38	80.3
3 years	16.24	86.4
5 years	15.4	86.4
10 years	15.4	178.9

Implantica AG Stock

Stocks

IMP A SDB

SE0014855029

Medical Equipment, Supplies & Distribution

Valuation: Implantica AG

Chart: Implantica AG

Latest news: Implantica AG

Last Transcript: Implantica AG

Analysts' recommendations: Implantica AG

Press Releases: Implantica AG

News in other languages: Implantica AG

Quotes and Performance

Price Extremes

Managers and Directors: Implantica AG

Latest insider transactions

Medical Equipment

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/31/26	Liselott Kilaas	Buy	Chairman	28,135	0.0484%
9/24/25	Andreas Öhrnberg	Sell	Chief Financial Officer	16,700	0.0287%
9/24/25	Andreas Öhrnberg	Sell	Chief Financial Officer	17,100	0.0294%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMPLANTICA AG	+2.38%	+4.55%	+12.98%	+285.17%	440M
ABBOTT LABORATORIES	-1.70%	+0.63%	-18.93%	+11.04%	181B
STRYKER CORPORATION	-1.54%	-0.98%	-21.45%	+15.09%	117B
MEDTRONIC PLC	-0.89%	-0.72%	-0.19%	+35.32%	116B
ESSILORLUXOTTICA	+3.89%	+20.80%	-42.56%	+8.20%	89.94B
CENCORA, INC.	-1.40%	-5.21%	-3.18%	+73.40%	62.97B
HOYA CORPORATION	+0.06%	-0.49%	+10.70%	+84.12%	55.43B
BECTON, DICKINSON AND COMPANY	-0.69%	+0.63%	+4.27%	-22.48%	53.49B
IDEXX LABORATORIES, INC.	-1.57%	+0.60%	-13.31%	+43.41%	44.92B
ALCON INC.	-0.66%	+3.26%	-4.83%	-8.81%	33.87B
Average	-0.22%	+2.62%	-7.65%	+52.44%	75.6B
Weighted average by Cap.	-0.61%	+2.44%	-13.15%	+24.43%

	2026 *	2027 *
Net sales	3.43M 3.83M 3.17M 2.88M 5.37M 363M 5.44M 38.01M 15.1M 190M 14.36M 14.05M 604M	9.14M 10.19M 8.44M 7.66M 14.31M 968M 14.49M 101M 40.21M 507M 38.25M 37.43M 1.61B
Net income	-20.78M -23.15M -19.18M -17.4M -32.51M -2.2B -32.91M -230M -91.35M -1.15B -86.9M -85.04M -3.65B	-25.61M -28.53M -23.65M -21.44M -40.08M -2.71B -40.57M -283M -113M -1.42B -107M -105M -4.5B
Net Debt	-28.02M -31.23M -25.88M -23.47M -43.86M -2.97B -44.4M -310M -123M -1.55B -117M -115M -4.93B	-1.71M -1.9M -1.58M -1.43M -2.67M -181M -2.7M -18.9M -7.5M -94.69M -7.14M -6.99M -300M